STOCK TITAN
  1. Home
  2. News
  3. ASLN

ASLAN Pharmaceuticals Ltd - ASLN STOCK NEWS

IMPACT
SENTIMENT
ASLN : Nasdaq
ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
clinical trial
IMPACT
SENTIMENT
ASLN : Nasdaq
ASLAN Pharmaceuticals Presents New Data From Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker Presentation at 32nd European Academy of Dermatology and Venereology Congress
clinical trial
IMPACT
SENTIMENT
ASLN : Nasdaq
ASLAN Pharmaceuticals Announces Acceptance of Late Breaker Abstract on Eblasakimab Phase 2b Results as Oral Presentation and Three Additional Abstracts at 32nd European Academy of Dermatology and Venereology Congress
clinical trial
IMPACT
SENTIMENT
ASLN : Nasdaq
ASLAN Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
conferences
IMPACT
SENTIMENT
ASLN : Nasdaq
ASLAN Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
earnings
IMPACT
SENTIMENT
ASLN : Nasdaq
Eblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy in Positive Phase 2b Study in Atopic Dermatitis
clinical trial
IMPACT
SENTIMENT
ASLN : Nasdaq
ASLAN Pharmaceuticals to Host Webcast on July 6, 2023, to Discuss Phase 2b Topline Data From TREK-AD Trial Evaluating Eblasakimab in Atopic Dermatitis
conferences clinical trial
IMPACT
SENTIMENT
ASLN : Nasdaq
ASLAN Pharmaceuticals Announces Publication in Clinical Immunology Highlighting Eblasakimab’s Unique Mechanism of Action in the Treatment of Atopic Dermatitis
IMPACT
SENTIMENT
ASLN : Nasdaq
ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan
IMPACT
SENTIMENT
ASLN : Nasdaq
ASLAN Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
conferences
Stock ASLN logo
ASLAN Pharmaceuticals Ltd
Nasdaq:ASLN

ASLN Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link

About ASLN

aslan pharmaceuticals (aslan, 6497.tt) is a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets. aslan targets diseases that are both highly prevalent in asia and orphan indications in the united states and europe. led by a senior management team with extensive experience in global and regional development and commercialization, aslan is headquartered in singapore and has offices in taiwan and china. aslan’s portfolio is comprised of four product candidates which target validated growth pathways applied to new patient segments, novel immune checkpoints and novel cancer metabolic pathways. aslan’s partners include array biopharma, bristol-myers squibb, almirall and csl.